"The Save Sight Institute leads the way in finding innovative new ways to preserve and restore vision lost to all eye diseases, including glaucoma, macular degeneration, retinal dystrophies, uveitis and inflammatory conditions."

During the past decade, Save Sight Institute conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Save Sight Institute" #1 sponsor was "University of Sydney" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Neurotech Pharmaceuticals" with 2 trials sponsored, "Apellis Pharmaceuticals, Inc." with 1 trials sponsored and "Bayer" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Save Sight Institute" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "The Lowy Medical Research Institute Limited" with 2 trials as a collaborator, "Center for Eye Research Australia" with 1 trials as a collaborator, "Marsden Eye Specialists" with 1 trials as a collaborator and "National Health and Medical Research Council, Australia" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Save Sight Institute" are "Diabetic Macular Oedema" (3 trials), "Geographic Atrophy" (3 trials), "Macular Edema" (3 trials), "Diabetic Retinopathy" (2 trials) and "Macular Telangiectasia Type 2" (2 trials). Many other conditions were trialed in "Save Sight Institute" in a lesser frequency.

Most popular intervention types in "Save Sight Institute" are "Drug" (13 trials), "Procedure" (5 trials), "Other" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (3 trials), "Sham Procedure" (3 trials), "Triamcinolone acetate" (3 trials), "Faricimab" (2 trials) and "Lampalizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Save Sight Institute" are 14 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Save Sight Institute". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Save Sight Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Save Sight Institute, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".